increase font size
Clinuvel is currently conducting three clinical trials of SCENESSE® (afamelanotide) as a photoprotective drug and one as a repigmentation therapy in nonsegmental vitiligo. In February 2012 Clinuvel filed a marketing authorisation application (MAA) for SCENESSE® with the European Medicines Agency.
In what has become something of a tradition in recent years, yet another country has used the new year to adopt further laws related to...
Read More
Allergan’s lawsuit filed against the FDA presents a relatively novel case in addressing the requirements of drug developers in relation...
Read More
Following on from last week’s conversation, I left off with the issues surrounding the off-label prescriptive habits by physicians and...
Read More
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut... Watch now |
